Ticker Hub
DRTS — AI Analysis & Sentiment
11 recent AI-generated analyses for DRTS. Sentiment and confidence insights updated continuously.
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
Alpha Tau's completion of pivotal trial enrollment is a key de-risking event for its lead therapy, moving it closer to market. This clinical milest...
May 8, 2026Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
Alpha Tau reported excellent Phase 1 clinical results for its pancreatic cancer therapy, showing high disease control and a strong safety profile. ...
May 4, 2026Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
FDA approval to expand Alpha Tau's pancreatic cancer trial is a significant positive catalyst, enhancing the company's clinical pipeline and future...
Apr 23, 2026Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
Alpha Tau, a clinical-stage oncology company, reported significant progress in regulatory approvals and clinical trials, alongside an improved cash...
Mar 9, 2026Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
Alpha Tau's recent Japanese marketing approval and positive clinical trial updates significantly de-risk its Alpha DaRT cancer therapy, despite ong...
Mar 9, 2026Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
Alpha Tau's substantial clinical and regulatory progress, including Japanese market approval and advancements in US trials for its Alpha DaRT thera...
Mar 9, 2026Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
Alpha Tau reported strong progress in its clinical trials and regulatory approvals, including Japanese marketing approval and multiple US trial adv...
Mar 9, 2026Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
Alpha Tau reported strong operational progress with a key Japanese marketing approval and positive clinical trial data. These advancements signific...
Mar 9, 2026Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
Alpha Tau, a clinical-stage oncology company, announced significant regulatory and clinical milestones, highlighted by Japanese marketing approval ...
Mar 9, 2026Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
Alpha Tau's recent Japanese marketing approval and advancements in US clinical trials create a strong bullish signal. Despite continued losses, an ...
Mar 9, 2026Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
Alpha Tau's strategic clinical and regulatory advancements in its Alpha DaRT cancer therapy, despite increased net losses, signal positive momentum...
Mar 9, 2026